Bone marrow-derived cells and hypertension

References

• Rauscher FM, Goldschmidt-Clermont PJ, Davis BH et al. Aging, progenitor cell exhaustion, and atherosclerosis. Circulation108(4), 457–463 (2003).
   PubMed Web of Science ®Google Scholar
• Anderson TJ. Prognostic significance of brachial flow-mediated vasodilation. Circulation115(18), 2373–2375 (2007).
   PubMed Web of Science ®Google Scholar
• Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N. Engl. J. Med.323(1), 22–27 (1990).
   PubMed Web of Science ®Google Scholar
• Ando J, Yamamoto K. Vascular mechanobiology: endothelial cell responses to fluid shear stress. Circ. J.73(11), 1983–1992 (2009).
   PubMed Web of Science ®Google Scholar
• Bhatia M, Bonnet D, Murdoch B, Gan OI, Dick JE. A newly discovered class of human hematopoietic cells with SCID-repopulating activity. Nat. Med.4(9), 1038–1045 (1998).
   PubMed Web of Science ®Google Scholar
• Goodell MA, Rosenzweig M, Kim H et al. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat. Med.3(12), 1337–1345 (1997).
   PubMed Web of Science ®Google Scholar
• Harraz M, Jiao C, Hanlon HD, Hartley RS, Schatteman GC. CD34- blood-derived human endothelial cell progenitors. Stem Cells19(4), 304–312 (2001).
   PubMed Web of Science ®Google Scholar
• Yoon CH, Hur J, Park KW et al. Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: the role of angiogenic cytokines and matrix metalloproteinases. Circulation112(11), 1618–1627 (2005).
   PubMed Web of Science ®Google Scholar
• van Zonneveld AJ, Rabelink TJ. Endothelial progenitor cells: biology and therapeutic potential in hypertension. Curr. Opin. Nephrol. Hypertens.15(2), 167–172 (2006).
   PubMed Web of Science ®Google Scholar
• Schmidt-Lucke C, Rossig L, Fichtlscherer S et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation111(22), 2981–2987 (2005).
   PubMed Web of Science ®Google Scholar
• Werner N, Nickenig G. Influence of cardiovascular risk factors on endothelial progenitor cells: limitations for therapy? Arterioscler. Thromb. Vasc. Biol.26(2), 257–266 (2006).
   PubMed Web of Science ®Google Scholar
• Loomans CJ, Dao HH, van Zonneveld AJ, Rabelink TJ. Is endothelial progenitor cell dysfunction involved in altered angiogenic processes in patients with hypertension? Curr. Hypertens. Rep.6(1), 51–54 (2004).
   PubMed Web of Science ®Google Scholar
• Werner N, Kosiol S, Schiegl T et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N. Engl. J. Med.353(10), 999–1007 (2005).
   PubMed Web of Science ®Google Scholar
• Oliveras A, Soler MJ, Martinez-Estrada OM et al. Endothelial progenitor cells are reduced in refractory hypertension. J. Hum. Hypertens.22(3), 183–190 (2008).
   PubMed Web of Science ®Google Scholar
• Oliveras A, de la Sierra A, Martinez-Estrada OM et al. Putative endothelial progenitor cells are associated with flow-mediated dilation in refractory hypertensives. Blood Press.17(5–6), 298–305 (2008).
   PubMed Web of Science ®Google Scholar
• Giannotti G, Doerries C, Mocharla PS et al. Impaired endothelial repair capacity of early endothelial progenitor cells in prehypertension: relation to endothelial dysfunction. Hypertension55(6), 1389–1397 (2010).
   PubMed Web of Science ®Google Scholar
• Zhong HL, Lu XZ, Chen XM et al. Relationship between stem cell factor/c-kit expression in peripheral blood and blood pressure. J. Hum. Hypertens.24(3), 220–225 (2010).
   PubMed Web of Science ®Google Scholar
• Yao EH, Yu Y, Fukuda N. Oxidative stress on progenitor and stem cells in cardiovascular diseases. Curr. Pharm. Biotechnol.7(2), 101–108 (2006).
   PubMed Web of Science ®Google Scholar
• Imanishi T, Moriwaki C, Hano T, Nishio I. Endothelial progenitor cell senescence is accelerated in both experimental hypertensive rats and patients with essential hypertension. J. Hypertens.23(10), 1831–1837 (2005).
   PubMed Web of Science ®Google Scholar
• Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension44(3), 248–252 (2004).
   PubMed Web of Science ®Google Scholar
• Silvestre J, Levy B. Circulating progenitor cells and cardiovascular outcomes: latest evidence on angiotensin-converting enzyme inhibitors. Eur. Heart J. Suppl.11(Suppl. E), E17–E21 (2009).
   Google Scholar
• Yildiz A, Gur M, Yilmaz R et al. Lymphocyte DNA damage and total antioxidant status in patients with white-coat hypertension and sustained hypertension. Turk. Kardiyol. Dern. Ars.36(4), 231–238 (2008).
   PubMedGoogle Scholar
• Sata M. Circulating vascular progenitor cells contribute to vascular repair, remodeling, and lesion formation. Trends Cardiovasc. Med.13(6), 249–253 (2003).
   PubMed Web of Science ®Google Scholar
• Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol. Rev.84(3), 767–801 (2004).
   PubMed Web of Science ®Google Scholar
• Caplice NM, Doyle B. Vascular progenitor cells: origin and mechanisms of mobilization, differentiation, integration, and vasculogenesis. Stem Cells Dev.14(2), 122–139 (2005).
   PubMed Web of Science ®Google Scholar
• Hill KL, Obrtlikova P, Alvarez DF et al. Human embryonic stem cell-derived vascular progenitor cells capable of endothelial and smooth muscle cell function. Exp. Hematol.38(3), 246.e1–257.e1 (2010).
   Web of Science ®Google Scholar
• Sata M, Fukuda D, Tanaka K et al. The role of circulating precursors in vascular repair and lesion formation. J. Cell. Mol. Med.9(3), 557–568 (2005).
   PubMed Web of Science ®Google Scholar
• You D, Cochain C, Loinard C et al. Hypertension impairs postnatal vasculogenesis: role of antihypertensive agents. Hypertension51(6), 1537–1544 (2008).
   PubMed Web of Science ®Google Scholar
• Pirro M, Schillaci G, Menecali C et al. Reduced number of circulating endothelial progenitors and HOXA9 expression in CD34+ cells of hypertensive patients. J. Hypertens.25(10), 2093–2099 (2007).
   PubMed Web of Science ®Google Scholar
• Ji R, Cheng Y, Yue J et al. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of microRNA in vascular neointimal lesion formation. Circ. Res.100(11), 1579–1588 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang C. MicroRNAs: role in cardiovascular biology and disease. Clin. Sci. (Lond.)114(12), 699–706 (2008).
   PubMed Web of Science ®Google Scholar
• Zhao T, Li J, Chen AF. MicroRNA-34a induces endothelial progenitor cell senescence and impedes its angiogenesis via suppressing silent information regulator 1. Am. J. Physiol. Endocrinol. Metab.299(1), E110–E116 (2010).
   PubMed Web of Science ®Google Scholar
• Sober S, Laan M, Annilo T. MicroRNAs miR-124 and miR-135a are potential regulators of the mineralocorticoid receptor gene (NR3C2) expression. Biochem. Biophys. Res. Commun.391(1), 727–732 (2010).
   PubMed Web of Science ®Google Scholar
• de Kloet ER, Van Acker SA, Sibug RM et al. Brain mineralocorticoid receptors and centrally regulated functions. Kidney Int.57(4), 1329–1336 (2000).
   PubMed Web of Science ®Google Scholar
• Hill JA, Olson EN. Cardiac plasticity. N. Engl. J. Med.358(13), 1370–1380 (2008).
   PubMed Web of Science ®Google Scholar
• Zhao Y, Samal E, Srivastava D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature436(7048), 214–220 (2005).
   PubMed Web of Science ®Google Scholar
• Latronico MV, Condorelli G. MicroRNAs and cardiac pathology. Nat. Rev. Cardiol.6(6), 419–429 (2009).
   PubMed Web of Science ®Google Scholar
• Urbich C, Kuehbacher A, Dimmeler S. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc. Res.79(4), 581–588 (2008).
   PubMed Web of Science ®Google Scholar
• Wang XH, Qian RZ, Zhang W et al. MicroRNA-320 expression in myocardial microvascular endothelial cells and its relationship with insulin-like growth factor-1 in Type 2 diabetic rats. Clin. Exp. Pharmacol. Physiol.36(2), 181–188 (2009).
   PubMed Web of Science ®Google Scholar
• Fish JE, Santoro MM, Morton SU et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev. Cell.15(2), 272–284 (2008).
   PubMed Web of Science ®Google Scholar
• Wang S, Aurora AB, Johnson BA et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev. Cell.15(2), 261–271 (2008).
   PubMed Web of Science ®Google Scholar
• van Solingen C, Seghers L, Bijkerk R et al. Antagomir-mediated silencing of endothelial cell specific microRNA-126 impairs ischemia-induced angiogenesis. J. Cell. Mol. Med.13(8A), 1577–1585 (2009).
   PubMed Web of Science ®Google Scholar
• Bahlmann FH, de Groot K, Mueller O et al. Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension45(4), 526–529 (2005).
   PubMed Web of Science ®Google Scholar
• Yu Y, Fukuda N, Yao EH et al. Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension. Am. J. Hypertens.21(1), 72–77 (2008).
   PubMed Web of Science ®Google Scholar
• Sugiura T, Kondo T, Kureishi-Bando Y et al. Nifedipine improves endothelial function: role of endothelial progenitor cells. Hypertension52(3), 491–498 (2008).
   PubMed Web of Science ®Google Scholar
• Umemura T, Soga J, Hidaka T et al. Aging and hypertension are independent risk factors for reduced number of circulating endothelial progenitor cells. Am. J. Hypertens.21(11), 1203–1209 (2008).
   PubMed Web of Science ®Google Scholar
• Llevadot J, Murasawa S, Kureishi Y et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J. Clin. Invest.108(3), 399–405 (2001).
   PubMed Web of Science ®Google Scholar
• Vasa M, Fichtlscherer S, Adler K et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation103(24), 2885–2890 (2001).
   PubMed Web of Science ®Google Scholar
• Gomez-Cerezo JF, Pagan-Munoz B, Lopez-Rodriguez M, Estebanez-Munoz M, Barbado-Hernandez FJ. The role of endothelial progenitor cells and statins in endothelial function: a review. Cardiovasc. Hematol. Agents Med. Chem.5(4), 265–272 (2007).
   PubMedGoogle Scholar
• Spadaccio C, Pollari F, Casacalenda A et al. Atorvastatin increases the number of endothelial progenitor cells after cardiac surgery: a randomized control study. J. Cardiovasc. Pharmacol.55(1), 30–38 (2010).
   PubMed Web of Science ®Google Scholar
• Balsari A, Marolda R, Gambacorti-Passerini C et al. Systemic administration of autologous, alloactivated helper-enriched lymphocytes to patients with metastatic melanoma of the lung. A Phase I study. Cancer Immunol. Immunother.21(2), 148–155 (1986).
   PubMed Web of Science ®Google Scholar
• Bataillard A, Freiche JC, Vincent M, Sassard J, Touraine JL. Antihypertensive effect of neonatal thymectomy in the genetically hypertensive LH rat. Thymus8(6), 321–330 (1986).
   PubMedGoogle Scholar
• Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem. Pharmacol.78(6), 539–552 (2009).
   PubMed Web of Science ®Google Scholar
• Guzik TJ, Hoch NE, Brown KA et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J. Exp. Med.204(10), 2449–2460 (2007).
   PubMed Web of Science ®Google Scholar
• Mann JF. What’s new in hypertension 2008? Nephrol. Dial. Transplant.24(1), 38–42 (2009).
   PubMed Web of Science ®Google Scholar
• Hoch NE, Guzik TJ, Chen W et al. Regulation of T-cell function by endogenously produced angiotensin II. Am. J. Physiol. Regul. Integr. Comp. Physiol.296(2), R208–R216 (2009).
   Google Scholar
• Shao J, Nangaku M, Miyata T et al. Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension42(1), 31–38 (2003).
   PubMed Web of Science ®Google Scholar
• Martin S, Tesse A, Hugel B et al. Shed membrane particles from T lymphocytes impair endothelial function and regulate endothelial protein expression. Circulation109(13), 1653–1659 (2004).
   PubMed Web of Science ®Google Scholar
• Martinez MC, Tesse A, Zobairi F, Andriantsitohaina R. Shed membrane microparticles from circulating and vascular cells in regulating vascular function. Am. J. Physiol. Heart Circ. Physiol.288(3), H1004–H1009 (2005).
   Web of Science ®Google Scholar
• Leroyer AS, Ebrahimian TG, Cochain C et al. Microparticles from ischemic muscle promotes postnatal vasculogenesis. Circulation119(21), 2808–2817 (2009).
   PubMed Web of Science ®Google Scholar
• Agouni A, Lagrue-Lak-Hal AH, Ducluzeau PH et al. Endothelial dysfunction caused by circulating microparticles from patients with metabolic syndrome. Am. J. Pathol.173(4), 1210–1219 (2008).
   PubMed Web of Science ®Google Scholar
• Boulanger CM, Amabile N, Guerin AP et al.In vivo shear stress determines circulating levels of endothelial microparticles in end-stage renal disease. Hypertension49(4), 902–908 (2007).
   PubMed Web of Science ®Google Scholar
• Brodsky SV, Zhang F, Nasjletti A, Goligorsky MS. Endothelium-derived microparticles impair endothelial function in vitro.Am. J. Physiol. Heart Circ. Physiol.286(5), H1910–H1915 (2004).
   PubMed Web of Science ®Google Scholar
• Preston RA, Jy W, Jimenez JJ et al. Effects of severe hypertension on endothelial and platelet microparticles. Hypertension41(2), 211–217 (2003).
   PubMed Web of Science ®Google Scholar
• Wang JM, Su C, Wang Y et al. Elevated circulating endothelial microparticles and brachial-ankle pulse wave velocity in well-controlled hypertensive patients. J. Hum. Hypertens.23(5), 307–315 (2009).
   PubMed Web of Science ®Google Scholar
• Mezentsev A, Merks RM, O’Riordan E et al. Endothelial microparticles affect angiogenesis in vitro: role of oxidative stress. Am. J. Physiol. Heart Circ. Physiol.289(3), H1106–H1114 (2005).
   PubMed Web of Science ®Google Scholar
• Dignat-George F, Camoin-Jau L, Sabatier F et al. Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome. Thromb. Haemost.91(4), 667–673 (2004).
   PubMed Web of Science ®Google Scholar
• Sangle SR, D’Cruz DP. Systemic hypertension in antiphospholipid syndrome. In: Hughes Syndrome: Antiphospholipid Syndrome. Khamashta MA (Ed.). Springer, London, UK, 112–116 (2006).
   Google Scholar
• Silva VJ, Machado MP, Voltarelli JC. Current status of cell therapy for systemic arterial hypertension. Expert Rev. Cardiovasc. Ther.7(11), 1307–1311 (2009).
   PubMedGoogle Scholar
• Nagaya N, Kangawa K, Kanda M et al. Hybrid cell-gene therapy for pulmonary hypertension based on phagocytosing action of endothelial progenitor cells. Circulation108(7), 889–895 (2003).
   PubMed Web of Science ®Google Scholar